DEVELOPMENT PIPELINE
We are leveraging our proprietary SNIPRx platform to discover, validate and build a robust clinical and pre-clinical pipeline of SL-based oncology therapeutics.
Development Pipeline
Program
Tumor Lesion
- Discovery Discovery
- IND-Enabling IND-Enabling
- Ph 1/2 Phase 1/2
- Pivotal Pivotal
Rights
Camonsertib
ATR Inhibitor
ATM + 16 lesions
- Ph 1/2
TRESR: Monotherapy
- Ph 1/2
TRESR: PARP (talazoparib) Combo
- Ph 1/2
ATTACC: PARP (olaparib/niraparib) Combo
- Ph 1/2
TRESR: Gemcitabine Combo

RP-6306
PKMYT1 Inhibitor
CCNE1,
FBXW7 + others
FBXW7 + others
- Ph 1/2
MYTHIC: Monotherapy
- Ph 1/2
MAGNETIC: Gemcitabine Combo
- Ph 1/2
MINOTAUR: FOLFIRI Combo
Clinical Trial
TRESR: Monotherapy
Progress
Phase 1/2
Clinical Trial
TRESR: PARP (talazoparib) Combo
Progress
Phase 1/2
Clinical Trial
ATTACC: PARP (olaparib/niraparib) Combo
Progress
Phase 1/2
Clinical Trial
TRESR: Gemcitabine Combo
Progress
Phase 1/2
Rights
Repare
Roche
Clinical Trial
MYTHIC: Monotherapy
Progress
Phase 1/2
Clinical Trial
MAGNETIC: Gemcitabine Combo
Progress
Phase 1/2
Clinical Trial
MINOTAUR: FOLFIRI Combo
Progress
Phase 1/2
Rights
Repare
Progress
Discovery
Rights
Repare
Progress
Discovery
Rights
Repare
Ono
Progress
Discovery
Rights
Repare
Progress
Discovery
Rights
Bristol Myers Squibb